Document is current
Any future updates will be listed below
-
Authors
Swoboda, David M. https://orcid.org/0000-0002-6102-1695
Kanagal-Shamanna, Rashmi https://orcid.org/0000-0001-7829-5249
Brunner, Andrew M.
Cluzeau, Thomas https://orcid.org/0000-0002-6745-1127
Chan, Onyee https://orcid.org/0000-0003-2872-1961
Al Ali, Najla
Montalban-Bravo, Guillermo
Gesiotto, Quinto J.
Gavralidis, Alexander
Hunter, Anthony M.
Lee, Jung-Hoon https://orcid.org/0000-0003-3683-9468
Kuykendall, Andrew T.
Talati, Chetasi https://orcid.org/0000-0002-2246-213X
Sweet, Kendra L.
Lancet, Jeffrey E. https://orcid.org/0000-0002-7751-7310
Padron, Eric https://orcid.org/0000-0002-4707-7916
Hussaini, Mohammad
Song, Jinming
Garcia-Manero, Guillermo https://orcid.org/0000-0002-3631-2482
Komrokji, Rami S. https://orcid.org/0000-0002-1876-5269
Sallman, David A. https://orcid.org/0000-0003-0504-8233
- License Information
-
More Information
Article History
Received: 27 July 2021
Revised: 8 November 2021
Accepted: 18 November 2021
First Online: 3 January 2022
Competing interests
: DMS, RKS, TC, OC, NAA, GMB, QJG, AG, AMH, JL, JS, and GGM declare no conflict of interest. AMB has done consulting for Novartis, BMS, Agios, Acceleron, and Takeda. ATK has done consulting for Abbvie, Blueprint, Celgene/BMS, Incyte, Novartis, PharmaEssentia, Protagonist, CTI Biopharma and has been part of a speaker’s bureau for Blueprint and Novartis. He receives research support from Sierra, Protagonist, and Prelude. CT is on advisory boards for Abbvie, BMS, Celgene, Daiichi Sankyo, Pfizer, and Novartis and has been part of a speaker’s bureau for Astellas, BMS, and Jazz. KS is on advisory committees for Arog, BMS, Gilead and Novartis. She has received research funding from Incyte and has received Honoraria from Stemline and Astellas. JEL has done consulting for AbbVie, Agios, Astella, Daiichi Sankyo, ElevateBio, Jazz, and Takeda and received Honoria from Agios. EP obtains research funding from Incyte, Kura Oncology, and BMS and has received Honoraria from Taiho. MH has done consulting and received honoraria from Adaptive Biotechnology, Stemline, Amgen, Seattle Genetics, BMS, Boston Biomedical, Decibio, Wells Fargo, Pivot and Blueprint Medicine. GGM RSK has been part of a speaker’s bureau for Jazz and BMS and received honoraria from JAZZ, BMS, Abbvie, Acceleron, Novartis, and Geron. DAS has received research funding from Aprea and Jazz, done consulting for AbbVie, Agios, Aprea, BMS, Incyte, Intellia, Kite, Magenta, Novartis, Shattuck Labs, and Takeda and part of a speaker’s bureau for BMS, Incyte. None of these relationships were related to the development of this manuscript.
